Amphastar Pharmaceuticals AMPH Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $171.17M-6.5% | $183.11M-4.6% | $191.84M+10.0% | $174.41M+2.3% | $170.53M-8.6% | ||
| $100.85M+3.5% | $97.44M+4.6% | $93.19M+6.0% | $87.92M+3.1% | $85.28M-14.6% | ||
| $70.32M-17.9% | $85.67M-13.2% | $98.65M+14.1% | $86.49M+1.5% | $85.25M-1.6% | ||
| 41.1%-5.7pp | 46.8%-4.6pp | 51.4%+1.8pp | 49.6%-0.4pp | 50%+3.5pp | ||
| $26.74M+14.7% | $23.31M+4.3% | $22.35M+11.3% | $20.08M-0.1% | $20.1M+10.8% | ||
| $11.93M+16.0% | $10.28M-10.7% | $11.51M+12.4% | $10.24M-13.7% | $11.87M+13.8% | ||
| $18.03M+9.5% | $16.47M-58.3% | $39.47M+182% | $13.99M-12.5% | $16M+23.6% | ||
| $56.69M+13.2% | $50.06M-31.7% | $73.33M+65.5% | $44.31M-7.6% | $47.96M+15.6% | ||
| $56.69M+13.2% | $50.06M-31.7% | $73.33M+65.5% | $44.31M-7.6% | $47.96M+15.6% | ||
| $13.63M-61.7% | $35.61M+40.6% | $25.32M-40.0% | $42.18M+13.1% | $37.29M-17.4% | ||
| 8%-11.5pp | 19.4%+6.2pp | 13.2%-11.0pp | 24.2%+2.3pp | 21.9%-2.3pp | ||
| $6.55M-1.2% | $6.63M+5.5% | $6.28M0.0% | $6.28M-0.1% | $6.29M-2.2% | ||
| $2.4M-0.9% | $2.42M+7.9% | $2.25M+16.9% | $1.92M-8.0% | $2.09M-8.9% | ||
| -$3.58M+3.1% | -$3.69M+3.0% | -$3.81M-33.6% | -$2.85M+55.7% | -$6.43M-444% | ||
| $10.05M-68.5% | $31.91M+48.3% | $21.51M-45.3% | $39.34M+27.5% | $30.86M-29.8% | ||
| $3.63M-51.5% | $7.49M+79.8% | $4.16M-49.9% | $8.31M+48.9% | $5.58M-7.0% | ||
| $6.42M-73.7% | $24.43M+40.8% | $17.35M-44.1% | $31.03M+22.7% | $25.29M-33.4% | ||
| 3.8%-9.6pp | 13.3%+4.3pp | 9%-8.7pp | 17.8%+3.0pp | 14.8%-5.5pp | ||
| $0.14-72.5% | $0.51+37.8% | $0.37-42.2% | $0.64+25.5% | $0.51-31.1% | ||
| $0.14-73.6% | $0.53+39.5% | $0.38-42.4% | $0.66+24.5% | $0.53-32.9% | ||
| 46.5M-3.6% | 48.2M+1.1% | 47.7M-0.9% | 48.1M-3.5% | 49.9M-4.2% | ||
| 45.3M-3.0% | 46.7M+0.6% | 46.5M-1.0% | 46.9M-1.5% | 47.6M-1.6% | ||
| $575K+11.7% | $515K+123% | $231K-84.7% | $1.51M+168% | -$2.23M-176% | ||
| $13.63M-61.7% | $35.61M+40.6% | $25.32M-40.0% | $42.18M+13.1% | $37.29M-17.4% | ||
| $27.98M-44.0% | $49.95M+26.6% | $39.45M-30.5% | $56.8M+11.6% | $50.9M-13.1% | ||
| $27.98M-44.0% | $49.95M+26.6% | $39.45M-30.5% | $56.8M+11.6% | $50.9M-13.1% | ||
| 16.3%-10.9pp | 27.3%+6.7pp | 20.6%-12.0pp | 32.6%+2.7pp | 29.8%-1.6pp | ||
| $13.63M-61.7% | $35.61M+40.6% | $25.32M-40.0% | $42.18M+13.1% | $37.29M-17.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amphastar Pharmaceuticals's revenue?
- Amphastar Pharmaceuticals (AMPH) generated $720.5M in revenue over the trailing twelve months, down 1.4% year over year.
- Is Amphastar Pharmaceuticals profitable?
- Amphastar Pharmaceuticals reported $79.2M in net income over the trailing twelve months, a 11.0% net margin.
- What are Amphastar Pharmaceuticals's profit margins?
- Gross margin is 47.3% and operating margin is 16.2%, with a 11.0% net margin.
- What is Amphastar Pharmaceuticals's earnings per share?
- Amphastar Pharmaceuticals's diluted EPS over the trailing twelve months is $1.66.
- Where does Amphastar Pharmaceuticals's income statement data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
